Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or 'Zombie' Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Natu
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company's broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called 'zombie' cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514558243/en/
Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience.
Dr. Quarta said, 'We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions.'1
About the Study
In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics.1
'Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,'1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. 'We appreciate the valuable support and expertise from the Rubedo team during this research.'
About Rubedo Life Sciences
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.
References
1. Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-01954-x
2. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514558243/en/
Investor Contact:
Rubedo Chief Business Officer Ali Siam
alisiam@rubedolife.com
781-974-9559
Media Contact:
Peter Collins
p.collins@togorun.com
908-499-1200
© Business Wire, Inc.
Disclaimer :
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AFP
16-05-2025
- AFP
Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or 'Zombie' Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Natu
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company's broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called 'zombie' cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue. This press release features multimedia. View the full release here: Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience. Dr. Quarta said, 'We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions.'1 About the Study In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics.1 'Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,'1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. 'We appreciate the valuable support and expertise from the Rubedo team during this research.' About Rubedo Life Sciences Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit References 1. Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). 2. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085. View source version on Investor Contact: Rubedo Chief Business Officer Ali Siam alisiam@ 781-974-9559 Media Contact: Peter Collins 908-499-1200 © Business Wire, Inc. Disclaimer : This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Euronews
17-04-2025
- Euronews
Top tips to convince your sleep-deprived teenager to ditch tech and go to bed earlier
ADVERTISEMENT Navigating bedtime with a teenager is, in many homes, a nightly battle with a constant refrain: "Get off your phone! Go to bed!" But bedtime routines aren't just for toddlers. Teenagers need them too, says Denise Pope, an expert on child development and a senior lecturer at the US-based Stanford University. Experts in adolescent sleep say a few small changes to how parents and teens approach sleep can make a dramatic difference. Here are some top tips to get your teenager to adopt healthier sleep habit. Related How much sleep do we really need? Here's what the experts say Try a tech-free bedtime routine for teens The first step to setting up a better bedtime routine is dealing with technology. Separate children from their devices at night. Phones, tablets, streaming services, and video games aren't the only things keeping kids up at night, but experts agree they are a major factor in delaying sleep. "Get the temptation out of the bedroom," Pope says. If the phone is within arm's reach, it's hard to ignore when notifications buzz. Many teens say they fall asleep while scrolling, or reach for their phone if they have trouble sleeping, and end up scrolling for hours. Be prepared for excuses. "My phone is my alarm clock" is something a lot of parents hear. The solution: Buy an alarm clock. Related In Denmark, schools are trialling later start times to give teens a sleep boost Put screens away an hour before bedtime. Exposure to light prevents the release of melatonin, the hormone released by the brain that makes us feel drowsy. Then, replace screens with a new wind-down routine. Try to get to bed around the same time each night and start winding down at least 30 minutes before. During that time, silence notifications, take a warm shower, or read a book. Avoid caffeine and energy drinks in the afternoon and evening. The best sleep environment is a cool, dark, quiet room. In noisy households, earplugs and a sleep mask can help. If a bedroom is too warm, it can affect getting to sleep and staying asleep, says adolescent sleep expert Kyla Wahlstrom. ADVERTISEMENT Related Body's internal clock could play a role in teens' late eating habits, researchers say Know the signs of sleep deprivation in teens Some of the telltale evidence of sleep deprivation: being irritable, grumpy, short-tempered, emotionally fragile, unmotivated, impulsive, and more likely to see the world and oneself through a negative lens. A sleep-deprived teen also may fall asleep during the daytime, in the car or in class. "We often blame adolescents for being lazy or unruly or having bad behaviour,** much of which could be attributed to the fact that they are chronically sleep-deprived," says Wendy Troxel, a clinical psychologist who has conducted numerous studies on adolescent sleep. How do you tell the difference between a sleepy teen and a cranky-but-well-rested one? One key sign is what sleep expert Joanna Fong-Isariyawongse calls 'zombie mornings'. ADVERTISEMENT We often blame adolescents for being lazy or unruly or having bad behaviour, much of which could be attributed to the fact that they are chronically sleep-deprived. Wendy Troxel Clinical psychologist "If your teen hits snooze five times, takes forever to get out of bed, asks you for a big cup of coffee first thing in the morning, most likely they are running on empty," says Fong-Isariyawongse, a neurologist at the University of Pittsburgh in the US. Extreme mood swings are another sign. Sleep is critical for emotional processing, which is why sleep-deprived teens are more likely to be irritable, anxious, or depressed. A sleep-deprived teen may also fall behind in school, because sleep is essential for learning and memory consolidation. Teens who sleep less are more likely to make bad choices when it comes to drug or alcohol use, drowsy or reckless driving, and risky sexual behaviour. If your teen sleeps until lunchtime on weekends, try to limit it to a couple hours. Otherwise, it throws off the body's internal clock and makes it harder to wake up when the new school week begins. ADVERTISEMENT Related Weighted blankets may improve sleep quality and reduce medication use among adults, study finds Why should teenagers care? Show them the science Explain to your teens why sleep matters, and that it's not just nagging parents who say so. Many studies show that depression, anxiety, and the risk of suicidal thinking go up as sleep goes down. Beyond mood, sleep deprivation affects physical and athletic ability. Teens who are sleep-deprived sustain more physical injuries, because they take more risks, their judgment is impaired, and reflexes and reaction times are not as fast. Teens who get more sleep perform better in sports, and when they do get injuries, they have a quicker recovery time. ADVERTISEMENT Related Teens' problematic smartphone use linked to anxiety, depression, and insomnia More teenage car accidents come from drowsy driving than driving under the influence of alcohol, studies show. Teens who say they get less than eight hours of sleep a night are more likely to text while driving, not wear a seat belt, drink and drive – or get in a car with a driver who has been drinking. As any parent knows, telling their teenager to go to sleep does not always work. You need to get their buy-in. "Kids need to be educated about sleep, and their brain health and emotional health, and how it all ties together," says Wahlstrom. ADVERTISEMENT
Euronews
05-04-2025
- Euronews
Shingles vaccine tied to a 20% lower risk of dementia among older people
ADVERTISEMENT Older adults who got the shingles vaccine may be at significantly lower risk of developing dementia, a new study in Wales has found. The study, which was published in the journal Nature , included about 283,000 older adults who were either deemed eligible or not to receive the shingles jab due to a quirk in Welsh vaccine policy. In 2013, Wales' government made 79-year-olds eligible for the shingles vaccine, and from then on, people aged into the programme when they turned 79. But due to limited supplies, adults who were 80 or older at the time were never offered the jab. Researchers from the US, Germany, and Austria homed in on people who turned 80 the week before the vaccine eligibility cutoff and compared them to those who turned 80 the following week. About half of those who were eligible got the vaccine. Related EU regulators block new Alzheimer's drug citing potentially fatal side effects After seven years, about one in eight people who did not get the vaccine had dementia. But those who got the jab were 20 per cent less likely to be diagnosed, the study found. The effects were much stronger among women than men. "It was a really striking finding," Dr Pascal Geldsetzer, the study's senior author and an assistant professor of medicine at Stanford University in the US, said in a statement. "This huge protective signal was there, any which way you looked at the data". Other studies have also suggested that the shingles vaccine could help keep dementia at bay. Last year, an analysis published in Nature Medicine showed that people who got a newer version of the shingles vaccine were at significantly lower risk of developing dementia in the six years after they were immunised. The two vaccines are made differently. The newer, more common jab contains a protein from the varicella zoster virus, which causes both chickenpox and shingles. The vaccine in the Welsh study used a weakened live version of the virus. Related Confronting 14 risk factors could delay or prevent nearly half of dementia cases, experts say In 2023, the UK phased out the live virus vaccine in favor of the newer jab from the drugmaker GSK because it appears to provide protection from shingles over a longer period of time. People can develop shingles – a painful rash of fluid-filled blisters that can take weeks to clear up – years after getting chickenpox if the dormant virus is reactivated. Older people and those with weakened immune systems are at higher risk. Both recent studies were natural experiments that are fairly similar to randomised trials, which are the gold standard for medical research. Because of the eligibility criteria for the shingles jab, the researchers were able to compare two otherwise similar groups of people, allowing them to identify the likely impact of vaccination. ADVERTISEMENT "What makes the study so powerful is that it's essentially like a randomised trial with a control group – those a little bit too old to be eligible for the vaccine – and an intervention group – those just young enough to be eligible," Geldsetzer said. Questions remain to prove causation The studies indicate that regardless of the type of jab, the shingles vaccine could offer some protection against dementia – though more research is needed to prove it. Related Experimental drug may slow dementia onset for patients with rare genetic form of Alzheimer's It also isn't clear what's driving the link. Geldsetzer's team said viruses that affect the nervous system may raise the risk of dementia, but the theory needs to be tested. Meanwhile, the disparity between women and men might be explained by differences in their immune systems, given they respond differently to infections and vaccinations, according to Dr Maxime Taquet, a clinical lecturer at Oxford University in the UK who led the 2024 study. ADVERTISEMENT "Even though this remains kind of hypothetical, we think this is playing a part in why we see a difference in men and women," Taquet told Euronews Health. To help solidify the evidence, the drugmaker GSK said last week that it is studying data from about 1.4 million older adults in the United Kingdom, some of whom got its shingles vaccine and some of whom did not. Similarly to the Welsh policy change, in 2023, the UK expanded its shingles vaccination programme from adults 70 and older to adults 65 and up – but those aged 66 to 69 at the time were told they had to wait until they were 70 to get the jab. Related Loneliness increases dementia risk by over 30%, new global analysis shows In another natural experiment, researchers will track whether they develop dementia symptoms. ADVERTISEMENT The recent findings on shingles vaccination could represent a new frontier for Alzheimer's research, which for decades has struggled to produce breakthroughs in prevention or new treatments. Alzheimer's disease is the most common form of dementia, which affects 7 million people in Europe, according to estimates from the European Brain Council. "Dementia is such a huge burden," Taquet said. "By triggering the right immune pathways in people, we might be able to reduce or even reverse the dementia process," he added. ADVERTISEMENT "There's many, many steps between where we are now and actually getting there, but I think this is an exciting new lead in this area".
